**ACPE Credit Information Sheet**

RSS: NDSHP Drug Therapy Related CE Series

“Triple therapy” in cardiovascular disease

Universal Activity Number (UAN): 0047-9999-16-037-L01-P

August 8th, 2017

In attempt to streamline the ACPE registration and evaluation process, NDSU has moved to an online format. Please complete the following no later than **September 8th, 2017 by 5:00pm**. After **September 8th, 2017,** the website will no longer be available, and we will not be able to issue credit.

**Register for ACPE credit by visiting:** <https://ndstate.co1.qualtrics.com/jfe/form/SV_0c7sukDudSyBKyF>

\*Pharmacists are required to provide their NABP ID to obtain credit. If this ID is not provided when registering, credit will not be issued.

How to Register for CPE Monitor:

Pharmacists are asked obtain their NABP e-Profile ID at [www.MyCPEmonitor.net](http://www.MyCPEmonitor.net) to ensure their e-Profile is properly setup prior to implementation of CPE Monitor. The e-Profile ID is required to receive credit for any ACPE-accredited CPE activities.

If you have any questions, please contact Larry Patnaude

at [Lawrence.patnaude@ndsu.edu](mailto:Lawrence.patnaude@ndsu.edu) or by calling 701-231-5178.

North Dakota State University College of Health Professions, School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**Attendance at the session and completion of the online evaluation are required to receive CE credit.**

Pharmacy professionals can now obtain CE statements of credit on the CPE Monitor website.



Disclosure of Speakers’ Conflicts of Interest

It is the policy of the continuing Pharmacy Education office to insure balance, independence, objectivity, and scientific rigor in all its individually or jointly presented CE programs. All faculty participating in NDSU College of Health Professions, School of Pharmacy CE programs are expected to disclose ANY real or apparent conflicts of interest that may have a direct bearing on the subject matter of the CE program. Disclosure pertains to relationships with any pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. This information will be obtained from all speakers and will be summarized in the program syllabus.

The intent of this policy is not to prevent a speaker with potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It remains for the audience to determine whether the speaker’s outside interests may reflect possible bias in either the exposition or the conclusions presented.

The presenters have indicated any significant financial interest or other affiliation with a commercial supporter of this session and/or with the manufacturer(s) of a commercial product.

The following speaker(s) has indicated the following real or apparent conflict(s) of interest to disclose relating to content of this program:

* **Stephanie Kling, PharmD, BCPS, Sanford Medical Center, Fargo, ND. The speaker has indicated she will be discussing off-label or investigational drug usage within the presentation.**